Active mutation in the epidermal growth factor receptor (EGFR) gene is highly correlated with the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKI). EGFR is among the indispensable biomarkers in selecting the therapeutic modality for NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.